Inhaled Canadian COVID-19 vaccine to enter Phase 2 human trials – CTV
Jan. 20, 2023
A new made-in-Canada COVID-19 vaccine that can be inhaled is set to enter Phase 2 human trials.
The vaccine is being developed at McMaster University in Hamilton, Ont.
“There is a pressing need to develop new, more effective next-generation vaccine strategies,” McMaster’s vice-president of research, Dr. Karen Mossman, said in a news release. “As international leaders in respiratory mucosal immunity and vaccines, our researchers pivoted quickly with the arrival of the COVID-19 pandemic, drawing on an already strong inhaled vaccine research program focused on tuberculosis.”
Pre-clinical trials have already shown that the inhaled aerosol vaccine can be more effective at creating immune responses than injected vaccines, partly because it targets the upper airways and lungs where respiratory viruses like COVID-19 enter the body, according to the release.
